Kazia Therapeutics 향후 성장

Future 기준 점검 2/6

Kazia Therapeutics은 연간 수입과 매출이 각각 54.8%와 69.8% 증가할 것으로 예상되고 EPS는 연간 64.4%만큼 증가할 것으로 예상됩니다.

핵심 정보

54.8%

이익 성장률

64.40%

EPS 성장률

Biotechs 이익 성장	24.6%
매출 성장률	69.8%
향후 자기자본이익률	n/a
애널리스트 커버리지	Low
마지막 업데이트	15 Jul 2026

최근 향후 성장 업데이트

Recent updates

Seeking Alpha • Jul 06

Kazia gains on FDA’s rare pediatric disease designation for childhood cancer therapy

The ADRs of Australian biotech Kazia Therapeutics (NASDAQ:KZIA) gained 8% Wednesday after the company announced that the U.S. Food and Drug Administration (FDA) granted the Rare Pediatric Disease Designation for an experimental therapy targeted at a form of childhood cancer. Paxalisib a brain-penetrant inhibitor received the designation as a treatment for atypical rhabdoid / teratoid tumors (AT/RT), a rare and highly aggressive childhood brain cancer, Kazia (KZIA) said in a press release. In awarding the RPD tag, the federal agency picks drug candidates targeted at serious and life-threatening diseases affecting less than 200K individuals in the U.S. with a primary impact on children aged 18 years or younger. If a drug with a rare pediatric disease designation wins FDA approval, the sponsor of its marketing application is entitled to receive a Priority Review Voucher (PRV) from the regulator. The PRVs valued at more than $100M historically, can be redeemed to receive a priority review for any subsequent marketing application, or it can be sold. In June, Kazia (KZIA) announced that the FDA awarded orphan drug designation for Paxalisib for the same condition.

이익 및 매출 성장 예측

NasdaqCM:KZIA - 애널리스트 향후 추정치 및 과거 재무 데이터 (AUD Millions)
날짜	매출	이익	자유현금흐름	영업현금흐름	평균 애널리스트 수
6/30/2029	18	-27	-28	-26	2
6/30/2028	0	-35	-28	-26	2
6/30/2027	0	-30	-28	-29	2
6/30/2026	0	-26	-27	-28	2
12/31/2025	2	-23	-14	-14	N/A
9/30/2025	2	-22	-14	-14	N/A
6/30/2025	2	-21	-13	-13	N/A
3/31/2025	2	-25	-12	-12	N/A
12/31/2024	3	-28	-12	-12	N/A
9/30/2024	2	-28	-11	-11	N/A
6/30/2024	2	-27	-10	-10	N/A
3/31/2024	1	-21	-11	-11	N/A
12/31/2023	0	-16	-13	-13	N/A
9/30/2023	0	-18	-14	-14	N/A
6/30/2023	0	-20	-15	-15	N/A
3/31/2023	0	-23	-18	-18	N/A
12/31/2022	N/A	-25	-20	-20	N/A
9/30/2022	0	-25	-21	-21	N/A
6/30/2022	0	-25	-23	-23	N/A
3/31/2022	8	-20	-15	-15	N/A
12/31/2021	15	-15	-8	-8	N/A
9/30/2021	15	-12	-9	-9	N/A
6/30/2021	15	-8	-9	-9	N/A
3/31/2021	8	-11	-14	-14	N/A
12/31/2020	0	-13	-18	-18	N/A
9/30/2020	1	-13	-14	-14	N/A
6/30/2020	1	-12	-9	-9	N/A
3/31/2020	1	-11	-7	-7	N/A
12/31/2019	1	-10	-5	-5	N/A
9/30/2019	1	-10	N/A	-6	N/A
6/30/2019	1	-10	N/A	-7	N/A
3/31/2019	2	-11	N/A	-6	N/A
12/31/2018	2	-12	N/A	-5	N/A
9/30/2018	3	-9	N/A	-7	N/A
6/30/2018	3	-6	N/A	-9	N/A
3/31/2018	4	-6	N/A	-10	N/A
12/31/2017	6	-6	N/A	-12	N/A
9/30/2017	7	-8	N/A	-12	N/A
6/30/2017	9	-11	N/A	-11	N/A
3/31/2017	7	-12	N/A	-12	N/A
12/31/2016	5	-12	N/A	-12	N/A
9/30/2016	4	-12	N/A	-12	N/A
6/30/2016	3	-12	N/A	-12	N/A
3/31/2016	3	-10	N/A	-12	N/A
12/31/2015	3	-9	N/A	-12	N/A
9/30/2015	2	-8	N/A	-9	N/A

애널리스트 향후 성장 전망

수입 대 저축률: KZIA 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 vs 시장: KZIA 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

고성장 수익: KZIA 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 대 시장: KZIA 의 수익(연간 69.8%)이 US 시장(연간 12.6%)보다 빠르게 성장할 것으로 예상됩니다.

고성장 매출: KZIA 의 수익(연간 69.8%)은 연간 20%보다 빠르게 증가할 것으로 예상됩니다.

주당순이익 성장 예측

향후 자기자본이익률

미래 ROE: KZIA의 자본 수익률이 3년 후 높을 것으로 예상되는지 판단하기에 데이터가 부족합니다.

성장 기업 찾아보기

기업 분석 및 재무 데이터 상태

데이터	최종 업데이트 (UTC 시간)
기업 분석	2026/07/27 14:58
종가	2026/07/24 00:00
수익	2025/12/31
연간 수익	2025/06/30

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
기업 재무제표	10년	손익계산서 현금흐름표 대차대조표	SEC 양식 10-K SEC 양식 10-Q
분석가 컨센서스 추정치	+3년	재무 예측 분석가 목표주가	분석가 리서치 보고서 Blue Matrix
시장 가격	30년	주가 배당, 분할 및 기타 조치	ICE 시장 데이터 SEC 양식 S-1
지분 구조	10년	주요 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
경영진	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발	10년	회사 공시	SEC 양식 8-K

^* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Kazia Therapeutics Limited는 6명의 분석가가 다루고 있습니다. 이 중 2명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가	기관
Kambiz Yazdi	BTIG
Soo Romanoff	Edison Investment Research
Sean Lee	H.C. Wainwright & Co.

Kazia Therapeutics 향후 성장

Future 기준 점검 2/6

핵심 정보

최근 향후 성장 업데이트

Consensus EPS estimates upgraded to AU$0.016 loss

Recent updates

New major risk - Revenue and earnings growth

Kazia Therapeutics Limited Announces Appointment of James Levine to Chief Financial Officer, Effective June 1, 2026

Consensus EPS estimates upgraded to AU$0.016 loss

Kazia Therapeutics Expands Ongoing Phase 1B Trial of Paxalisib in Advanced Breast Cancer

Kazia Therapeutics Limited Appoints Dr. Sudha Rao as Chief Scientific Officer

Kazia Therapeutics Limited Expands Oncology Platform with First-In-Class SETDB1 Inhibitor Drug Development Platform

First half 2026 earnings released: AU$4.02 loss per share (vs AU$12.29 loss in 1H 2025)

New major risk - Negative shareholders equity

Kazia Therapeutics Limited has filed a Follow-on Equity Offering in the amount of $100 million.

Kazia Therapeutics Announces Compelling Preclinical and Translational Data for Nuclear PD-L1 Degrader (NDL2)

Kazia Therapeutics Reports Encouraging Preliminary Clinical Responses in Ongoing Phase 1B Study of Paxalisib in Late-Stage Metastatic Triple-Negative Breast Cancer

Kazia Therapeutics Highlights New Clinical and Translational Findings Demonstrating Paxalisib's Ability to Reinvigorate Anti-Tumor Immunity Across Multiple Advanced Breast Cancer Populations Including TNBC and HER2+

Kazia Therapeutics Limited announced that it expects to receive $50.000896 million in funding from ADAR1 Capital Management, LLC, Ikarian Capital, LLC, Stonepine Capital Management LLC, Velan Capital Partners LP, Revach Capital Management LLC

Kazia Therapeutics Limited Achieves Initial iCR (Immune- Complete Response) in Metastatic TNBC and Delivers Fourth Quarter Business Update with Breakthroughs Across Breast Cancer, Immuno-Oncology, and GBM Regulatory Strategy

Kazia Therapeutics Limited announced delayed 20-F filing

Kazia Therapeutics Limited Plans to Request Type C Meeting with U.S. Food & Drug Administration to Discuss Overall Survival Data in GBM and Potential NDA Filing in Alignment with FDA Initiative Project FrontRunner

Kazia Therapeutics Announces 86% Reduction in Tumor Burden in Expanded-Access Case of Metastatic Tnbc Patient Treatment with Paxalisib-Immunotherapy Regimen

Kazia Therapeutics Reports Complete Ex Vivo Disruption of Large Circulating Tumor Cell Clusters in Stage Iv Her2-Positive Breast Cancer with Paxalisib Monotherapy

Kazia Therapeutics Limited announced that it expects to receive $2.049992 million in funding

Kazia Therapeutics Limited has filed a Follow-on Equity Offering in the amount of $1.906196 million.

Kazia Therapeutics Reports Early Efficacy Data from First Triple-Negative Breast Cancer Patient Receiving Paxalisib Combination Regimen Achieves >50% Reduction in Circulating Tumor Cells in Phase 1B Trial

First half 2025 earnings released: AU$12.29 loss per share (vs AU$18.40 loss in 1H 2024)

Kazia Therapeutics Announces Transformative Preclinical Data Demonstrating Paxalisib's Potential to Overcome Immunotherapy Resistance in Triple-Negative Breast Cancer

Kazia Therapeutics Limited Announces First Patient Dosed in Phase 1b Trial of Paxalisib in Advanced Breast Cancer

New minor risk - Financial data availability

High number of new and inexperienced directors

Kazia Therapeutics Limited Announces the Launch of A Groundbreaking Trial with Paxalisib in Combination with Immunotherapy in Women with Advanced Breast Cancer

Kazia Therapeutics Limited has completed a Follow-on Equity Offering in the amount of $1.999922 million.

Kazia Therapeutics Limited has filed a Follow-on Equity Offering in the amount of $2 million.

Kazia Therapeutics Limited Provides Update on Paxalisib Regulatory Pathway Following Type C Meeting with FDA

Kazia Therapeutics Limited Announces to Present Data Highlighting Synergistic Activity Between Paxalisib and Immunotherapy in Immunotherapy-Resistant Triple Negative Breast Cancer Model at the San Antonio Breast Cancer Symposium

Kazia Therapeutics Limited Announces Granting of Type C Meeting with FDA to Discuss Potential Next Steps for Paxalisib in the Treatment of Newly Diagnosed Glioblastoma Multiforme

Kazia Therapeutics Limited announced delayed 20-F filing

New minor risk - Financial data availability

Kazia Therapeutics Announces Presentation of Evt801 Clinical Data At 15 Biennial Ovarian Cancer Research Symposium

New major risk - Market cap size

Kazia Therapeutics Limited has completed a Follow-on Equity Offering in the amount of $10 million.

Kazia Therapeutics Limited Announces Phase II/III Clinical Trial Results for Paxalisib in Glioblastoma

Kazia Therapeutics Limited Reports Successful Stage 1 Completion of the EVT801 Phase 1 Clinical Trial in Advanced Cancer Patients

Kazia Therapeutics Limited announced that it expects to receive $15 million in funding from Alumni Capital LP

New major risk - Share price stability

New major risk - Financial position

New minor risk - Financial data availability

Kazia Therapeutics Limited Reports Early Conclusion of Clinical Trial After Reaching Primary Endpoint

Kazia Therapeutics Limited Announces Appointment of Board Members

Kazia Therapeutics Limited Announces Executive Changes

New major risk - Revenue and earnings growth

New major risk - Shareholder dilution

Kazia Therapeutics Limited has completed a Follow-on Equity Offering in the amount of $1.981756 million.

Kazia Therapeutics Announces Receipt of Nasdaq Minimum Bid Notification

High number of new and inexperienced directors

Kazia Therapeutics Provides Preliminary Update from Ongoing Phase 2 Study of Paxalisib in Primary Cns Lymphoma

Kazia Therapeutics Limited Announces Clinical Data At ESMO 2023 from Ongoing Phase 1 ESMO Study

Kazia Therapeutics Limited Announces Acceptance of Late-Breaking Abstracts and Oral Presentation of Pnoc022 Clinical Data At 2023 Society for Neuro-Oncology Annual Meeting

Kazia Therapeutics Limited, Annual General Meeting, Nov 08, 2023

Kazia Therapeutics Limited Announces Change to Board of Directors

Kazia Therapeutics Limited Appoints John Friend as Managing Director

Kazia Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 4.5 million.

Kazia Therapeutics Limited Receives Fast Track Designation from FDA for Treatment of Solid Tumor Brain Metastases Harboring PI3K Pathway Mutations in Combination with Radiation Therapy

Kazia Therapeutics Limited Announces Phase II Clinical Study to Investigate Paxalisib in Recurrent/Progressive IDH-Mutant Grade 2 & 3 Glioma

Kazia Therapeutics Limited Appoints Ms. Ebru Davidson to its Board

Kazia gains on FDA’s rare pediatric disease designation for childhood cancer therapy

이익 및 매출 성장 예측

애널리스트 향후 성장 전망

주당순이익 성장 예측

향후 자기자본이익률

성장 기업 찾아보기

기업 분석 및 재무 데이터 상태

데이터 소스

분석 모델 및 스노우플레이크

산업 및 섹터 지표

분석가 소스